Meloxicam Articles
Boehringer opens new Japanese R&D center
1 December 2008
463 generics added to Japan's NHI list
14 July 2008
Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M
14 April 2008
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
13 new drugs added to Japan's NHI list
19 March 2007
Actavis launches generic meloxicam in USA
31 July 2006
FDA approves first generic meloxicam
24 July 2006
Daiichi Sankyo sees increase in 2005 income
20 February 2006
Abbott:13.4% 4th-qtr 2005 EPS growth, as expected
6 February 2006
Better-than-expected 1st qtr for Daiichi
22 August 2005
Pfizer's Celebrex gains from Bextra withdrawal
30 May 2005
Daiichi FY2005 net income soars 39%
16 May 2005
Japan stock market week to March 28
4 April 2005
US FDA panel says COX-2s can be sold, OKs Vioxx' return to market?
28 February 2005
Vioxx withdrawal will not hurt COX-2s initially, says NOP survey
8 November 2004
Tokyo pharma stocks - week to October 4
11 October 2004
Daiichi Pharma
23 August 2004
Boehringer Ingelheim's Mobic cleared for RA
16 August 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
UK parliament
28 January 2002
Stock Commentary - Tokyo
15 November 2001
Solid first-half 2001 for Boeh Ingelheim
29 August 2001
Stock Commentary - Tokyo
8 February 2001
BI gets approvable letter for Mobic in USA
21 December 1999
Daiichi Pharma sales growth slower; Harmokisan approval delayed
15 November 1999
1st qtr net earnings up 13% for Abbott Labs
13 April 1999
Sun Pharma introduces nine new drugs
12 March 1999
Mobic's US prospects boosted by Abbott deal
11 March 1999
Boeh Ingelheim & Abbott in US marketing deal
4 March 1999
Boehringer Ingelheim submits Mobic NDA - updated story
7 January 1999
Boehringer Ingelheim submits NDA for Mobic
21 December 1998
Pivotal Studies Of Celebrex Unveiled At ACR
19 November 1998
D&TB Revisits Aricept; Remains "Unconvinced"
10 September 1998
Abbott Labs Impacted By Strength Of Dollar
14 July 1998
Sales Well Up And Solid Growth At Boehringer Ingelheim
26 August 1997
UK Industry Code Of Practice In 1996
24 March 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Searle Reports Progress With COX-2 Inhibitor
21 October 1996
UK Launch Of Boeh Ingelheim's NSAID Meloxicam
9 September 1996
Merck's New Drugs For Arthritis And Infections
27 May 1996
First Launch Of Boeh Ingelheim's Meloxicam
20 May 1996
Boeh Ingelheim To Focus On Alliances
20 May 1996
Boeh Ingelheim Counts On New Drugs For Success
27 November 1995
BOEHRINGER INGELHEIM REDEFINES STRATEGIES
30 May 1994
Showing 1-72 of 72 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
